Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients

Figure 2

Freedom from CMV (a) or EBV (b) viremia with >30 copies/PCR and BKV (c) viremia with >1500 copies/ml in DES (blue) and non-DES (red) patients during the 1st 5 years after transplant. The group differences were assessed by the log-rank test.

(a) CMV viremia with >30 copies/PCR

(b) EBV viremia with >30 copies/PCR

(c) BKV viremia with >1500 copies/ml